Moon Surgical

Explainers

Plain-language answers to the questions people ask about Moon Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

• What is a surgical robot?

  A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.

• What is Moon Surgical Maestro?

  Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework: FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verification). EDITORIAL DISTINCTION: assistive-laparoscopy positioning. Maestro augments surgeons within existing laparoscopic procedures rather than replacing them as full surgical platforms (Intuitive da Vinci, Medtronic Hugo, CMR Versius, J&J Ottava). Smaller-footprint OR integration + commercial-niche positioning. Per DEPLOY's surgical cluster framework, Maestro is the cohort's genuine shipped assistive-AI exemplar within the broader replacement-robotics cluster. Cohort positioning: assistive-laparoscopy commercial-niche archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance (Wave 2).

• How did DEPLOY correct the Moon Maestro FDA clearance date?

  DEPLOY's Moon Maestro entity anchor originally framed FDA 510(k) clearance as 'December 2023 (specific K-number at cap-flag pending primary-source confirmation).' The framing was honest cap-flag discipline at the time: month-precision claim with K-number explicitly held at cap-flag pending primary-source-anchored verification. Primary-source FDA database research per Agent A surfaces K240598 cleared June 2024. Both the K-number resolves (K240598) AND the date was off by six months (June 2024, not December 2023). The reconciliation operates as a worked example of DEPLOY's verified-vs-claimed framework applied recursively to DEPLOY's own corpus: cap-flag-honestly until primary source confirms; update + surface the change transparently via inline editorial-transparency footer + framework-in-action correction narrative when primary source surfaces. The catch is the discipline operating on itself. Per [DEPLOY's framework discipline](/explainers/how-deploy-verifies), recursive application of cap-flag + primary-source-anchored verification on DEPLOY's own published corpus + transparent surfacing of correction in entity-anchor footer + canonical worked-example narrative at correction-tier depth compounds editorial credibility at the operational-practice layer.

• How does DEPLOY think about robot insurance?

  DEPLOY thinks about robot insurance as a four-dimension actuarial framework operating recursively across the verified-vs-claimed throughline: deployment-incident-recall actuarial depth (61 verified incidents at primary-source-anchored severity + root-cause + regulatory-action depth; exposure denominators absent at most deployments); manufacturer financial-state / counterparty risk (114 investors + 58 funding rounds + 29 acquisitions verified; financial state vs relationship state distinction); supply-chain component failure analysis (absent as structured substrate; bounded to safety-critical components when authored); regulatory clearance per jurisdiction (34 verified filings lopsided 94% US-FDA-only; jurisdictional completeness is the load-bearing gating layer for insurability per region). The discipline that distinguishes DEPLOY's framework from the broader insurance-discourse cohort: honest 'insurability unknown for this region / no exposure data' is more valuable than a fabricated rate. Cap-flag-as-trust-signal operates recursively on actuarial framing.

Current leadership (2)

• Anne Osdoit Founding CEOIR-verified
• Brice Gayet FounderIR-verified

Founders (2)

• Anne Osdoitcofounderfounded 2018-01-01
• Brice Gayetcofounderfounded 2018-01-01

Board (1)

• Frederic Moll director

Safety record

No incidents on record for Moon Surgical.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Peer companies

• Johnson & Johnson3 models
• Intuitive Surgical2 models
• LEM Surgical2 models
• MicroPort MedBot2 models
• Neocis2 models
• Stryker2 models

Financial state

Reporting basis

aggregator_estimate

Lifecycle stage

growth

Counterparty risk class

moderate

Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.

Funding rounds (2)

• Series B2023-01-25

  $82M(reported)

  Investors: Sofinnova Partners (lead), OrbiMed

• Series A2021-06-01

  $16M(reported)

  Investors: Sofinnova Partners (lead), Sectoral Asset Management

Regulatory filings (2)

• K240598fda 510k · us_fdacleared2024-03-04

  Linked models: Maestro

• K240598fda 510k · us_fdacleared2024-01-01

  Linked models: Maestro

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

• Verified media added✓VerifiedJun 4, 2026

  Maestro Overview

• Record createdJun 3, 2026

  Added to the verified registry

• Deployment verified✓VerifiedSep 26, 2023

  Maestro at Jacksonville

Full change history →

Sources (4)

1. https://www.prnewswire.com/news-releases/moon-surgical-second-fda-clearance-commercial-maestro ↗
2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K240598 ↗
3. https://www.biospace.com/moon-surgical-scopilot-fda-nvidia-holoscan ↗
4. https://www.massdevice.com/moon-surgical-funding-fred-moll/ ↗

Common questions

What is Moon Surgical?

Surgical-robotics company (Paris + San Carlos CA; CEO Anne Osdoit, chair Fred Moll) making the Maestro laparoscopic surgical-assistant robot with the shipped FDA-cleared ScoPilot AI (NVIDIA Holoscan).

What does Moon Surgical make?

Moon Surgical has 1 robot model on the DEPLOY registry: Maestro (Moon Surgical builds both physical robots and the AI that runs them).

Is Moon Surgical publicly traded?

No. Moon Surgical is privately held and not publicly traded, per the DEPLOY registry.

Who competes with Moon Surgical?

On the DEPLOY registry, peer companies to Moon Surgical building in the same form factors include Johnson & Johnson, Intuitive Surgical, LEM Surgical, MicroPort MedBot.

Who is the CEO of Moon Surgical?

Anne Osdoit is the ceo of Moon Surgical, per the DEPLOY registry.